119 related articles for article (PubMed ID: 37723934)
1. What is the impact of a Hepatitis C 'test, trace and treat' pilot using peer workers?
Caroline A; Kate M; Roberts M; Ryan J; Murphy S; Richardson C; Coyte A; Taha Y; Stuart M
J Viral Hepat; 2023 Dec; 30(12):922-925. PubMed ID: 37723934
[TBL] [Abstract][Full Text] [Related]
2. Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
Askar S; Jelley R; McQue K; Allsop C; McCullough F; Miller C; Taha Y; Masson S; McPherson S
J Viral Hepat; 2022 Aug; 29(8):685-690. PubMed ID: 35643915
[TBL] [Abstract][Full Text] [Related]
3. Integration of Hepatitis C and Addiction Treatment in People Who Inject Drugs: The San Patrignano HCV-Free and Drug-Free Experience.
Piselli P; Boschini A; Gianfreda R; Nappo A; Cimaglia C; Scarfò G; Smacchia C; Paoletti R; Duehren S; Girardi E
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543741
[TBL] [Abstract][Full Text] [Related]
4. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.
Hsu JT; Hsu PI; Shie CB; Chuah SK; Wu IT; Huang WW; Tang SY; Tsai KF; Kuo LF; Ghose S; Hsu JC; Shih CA
Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334612
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C reinfection in former and active injecting drug users in Belgium.
Busschots D; Bielen R; Koc ÖM; Heyens L; Verrando R; de Galocsy C; Van Steenkiste C; Nevens F; Midgard H; Dalgard O; Robaeys G
Harm Reduct J; 2021 Oct; 18(1):102. PubMed ID: 34641896
[TBL] [Abstract][Full Text] [Related]
8. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
[TBL] [Abstract][Full Text] [Related]
9. Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs.
Hassan MRA; Chan HK; Nordin M; Yahya R; Sulaiman WRW; Merican SAA; Lah D; Sem X; Shilton S
Harm Reduct J; 2023 Apr; 20(1):48. PubMed ID: 37046294
[TBL] [Abstract][Full Text] [Related]
10. Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
Hibbert M; Simmons R; Harris H; Desai M; Sabin CA; Mandal S
J Viral Hepat; 2023 Aug; 30(8):646-655. PubMed ID: 36929670
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway.
Midgard H; Ulstein K; Backe Ø; Foshaug T; Sørli H; Vennesland K; Nilssen D; Dahl EH; Finbråten AK; Wüsthoff L; Dalgard O
Int J Drug Policy; 2021 Oct; 96():103165. PubMed ID: 33642182
[TBL] [Abstract][Full Text] [Related]
12. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
13. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF
J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228
[TBL] [Abstract][Full Text] [Related]
15. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
[TBL] [Abstract][Full Text] [Related]
16. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
[TBL] [Abstract][Full Text] [Related]
17. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J
Clin Infect Dis; 2021 Apr; 72(8):1392-1400. PubMed ID: 32166305
[TBL] [Abstract][Full Text] [Related]
18. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort.
Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Dore GJ; Matthews GV;
Int J Drug Policy; 2021 Oct; 96():103422. PubMed ID: 34426040
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
